Education
About Us
Working with TipRanks
Follow Us
Anbio Biotechnology Class A (NNNN)
NASDAQ:NNNN
NNNN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.18 - $38.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)131.28K
Market Cap
$5.32B
Enterprise Value$232.26M
Total Cash (Recent Filing)$11.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)610.4
Beta1.33
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding43,891,200
10 Day Avg. Volume316,766
30 Day Avg. Volume131,276
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)14.19
Price to Sales (P/S)0.00
P/FCF Ratio117.30
Enterprise Value/Market Cap0.04
Enterprise Value/Revenue7.82
Enterprise Value/Gross Profit36.49
Enterprise Value/Ebitda20.47
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NNNN FAQ
What was Anbio Biotechnology Class A’s price range in the past 12 months?
Anbio Biotechnology Class A lowest stock price was $5.18 and its highest was $38.50 in the past 12 months.
What is Anbio Biotechnology Class A’s market cap?
Anbio Biotechnology Class A’s market cap is $5.32B.
When is Anbio Biotechnology Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anbio Biotechnology Class A’s earnings last quarter?
Currently, no data Available
Is Anbio Biotechnology Class A overvalued?
According to Wall Street analysts Anbio Biotechnology Class A’s price is currently Overvalued.
Does Anbio Biotechnology Class A pay dividends?
Anbio Biotechnology Class A does not currently pay dividends.
What is Anbio Biotechnology Class A’s EPS estimate?
Anbio Biotechnology Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anbio Biotechnology Class A have?
Anbio Biotechnology Class A has 43,891,200 shares outstanding.
What happened to Anbio Biotechnology Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anbio Biotechnology Class A?
Currently, no hedge funds are holding shares in NNNN
Company Description
Anbio Biotechnology Class A
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. Our comprehensive range encompasses solutions for various applications, including over-the-counter utilization, point-of-care settings, and laboratory applications. Our IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. These domains encompass infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes.
Technical Analysis
HealthStream
―
US Physical Therapy
―
Spyre Therapeutics
―
RxSight
―
Structure Therapeutics, Inc. Sponsored ADR
―